NCT01867736已完成不适用
BIOTRONIK's - First in Men Study of the Passeo-18 LUX Drug Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Subjects Requiring Revascularization of Infrapopliteal Arteries (BIOLUX P-II).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Biotronik AG
- 入组人数
- 72
- 试验地点
- 6
- 主要终点
- Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).
研究概览
简要总结
A prospective, multicentric, randomized controlled trial to assess the safety and performance of the Passeo-18 Lux Paclitaxel releasing PTA balloon catheter versus the uncoated Passeo 18 PTA balloon catheter for the treatment of stenosis, restenosis or occlusion of the infrapopliteal arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent.
- •Subject is willing and able to comply with follow-up evaluations.
- •Subject is ≥ 18 years old.
- •Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries ≥ 30 mm. Lesions should not extend beyond the ankle joint.
- •A maximum of 2 different vessels can be treated: successful wire crossing is required for the first target vessel before randomization occurs.
- •Subject with PAD or critical limb ischemia according to the current guidelines in need for urgent revascularization to relieve symptoms and improve walking capacity.
- •Reference Vessel Diameter (RVD) 2 - 4 mm, based on visual estimation.
- •Inflow free from flow-limiting lesion confirmed by angiography. Patients with flow-limiting inflow lesions (> 50% stenosis) can be included if lesion(s) have been treated successfully before the index procedure, with a maximum residual stenosis of 30% per visual assessment.
- •At least one non-occluded crural vessel with angiographically documented run-off to the foot.
- •Successful wire crossing of the lesion.
排除标准
- •Flow-limiting (> 50% DS) inflow lesion proximal to target lesion, left untreated.
- •Failure to obtain <30% residual stenosis in a pre-existing haemodynamically significant (>50% DS) inflow lesion (DEB or DES not allowed for the treatment of inflow lesions).
- •Infrapopliteal lesions extending beyond the ankle joint and involving crural vessels.
- •Acute thrombus in the target vessel (eg complication of inflow lesion treatment) documented by angiogram, if not treated successfully prior to enrolment).
- •Planned major amputation above the ankle of target limb, or any other planned major surgery within 30 days post-procedure.
- •Previous bypass surgery of target vessel.
- •Previously implanted stent in target lesion.
- •Haemorrhagic diathesis or coagulopathy or other disorders such as gastrointestinal ulcerations or cerebral disorders that would restrict prescription of dual anti-platelet therapy.
- •Subject with hepatic failure, deep vein thrombosis, thrombophlebitis, systemic lupus erythematous or subject is on immunosuppressant therapy.
- •Subject with acute MI ≤ 3 months.
- •Renal failure with a creatinine of ≥ 2,5 mg/dl, except patients currently on regular dialysis.
- •Phenprocoumon intake, except for patients who are treated for Arterial Fibrillation. For these patients Phenprocoumon treatment can be interrupted and re-started after treatment with Dual Antiplatelet Therapy for 4 weeks post procedure.
- •Known allergy to contrast media used for angiography that cannot be controlled by pre-medication with steroids and/or antihistaminica.
- •Allergy, intolerance or hypersensitivity to Paclitaxel or related compounds and/or to the delivery matrix n-Butyryl tri-n-hexyl citrate(BTHC).
- •Co- morbid conditions limiting life expectancy ≤ 1 year.
- •Patients that are under active treatment for cancer; Patients, who have been successfully treated for cancer in the past, can be included.
- •Subject is participating in another clinical device trial where the primary endpoint has not yet been reached.
- •Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study.
结局指标
主要结局
Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).
时间窗: 6 months
Safety: Major adverse event rate (MAE), defined as all cause death, major amputation of target extremity, target lesion thrombosis, target lesion revascularisation (TLR)and target vessel revascularization (TVR) at 30 days.
时间窗: 30 days
次要结局
- Target lesion failure, assessed by target lesion revascularization (TLR) rate at 6 months and 12 months(6 and 12 months)
- Change in Rutherford classification at 30 days, 6 months and 12 months(30 days, 6 months and 12 months)
- Duplex based primary patency at 30 days, 6 months and 12 months(30 days, 6 months and 12 months)
- Major adverse event rate, defined as all cause death, major amputation of target extremity, target lesion thrombosis, TLR and TVR at 6 months and 12 months(6 and 12 months)
- Change in mean ABI at discharge, 30 days, 6 months and 12 months(Discharge, 30 days, 6 months and 12 months)
- Quality of life evaluation, assessed by EQ5D questionnaire at baseline, 30 days, 6 months and 12 months(Baseline, 30 days, 6 months and 12 months)
- Procedural success, defined as successful vascular access, completion of endovascular procedure and immediate morphologic success with a residual stenosis <30%.(Day 0)
- Device success, defined as exact deployment according to Instructions For Use(Day 0)
- Technical success, defined as device or procedural success without the occurrence of major adverse events during the hospital stay.(Participants will be followed for the duration of hospital stay, an expected average of 1-2 days)
- Target vessel revascularization (TVR) rate at 6 months and 12 months(6 and 12 months)
- Late Lumen Loss(6-months post-procedure)
- Binary re-stenosis rate at 6 months, assessed by QVA(6 months)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
不适用
First in Men Study: BIOMAG-ICoronary Artery DiseaseNCT04157153Biotronik AG116
已完成
不适用
ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable StentCoronary Artery DiseaseNCT01761578Arterial Remodeling Technologies30
已完成
不适用
BIOLUX P-I First in Man StudyVascular DiseasePeripheral Artery DiseaseAtherosclerosisArteriosclerosisNCT01221610Biotronik AG60
终止
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsAdvanced TumorsNon-Small-Cell Lung CancerErdheim-Chester DiseaseMelanomaOther RAS/RAF/MEK/ERK Mutated TumorsNCT04198818Haihe Biopharma Co., Ltd.37
终止
1 期
BAY1238097, First in ManNeoplasmsNCT02369029Bayer8